共 50 条
- [41] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomyANNALS OF ONCOLOGY, 2020, 31 : S559 - S560Albiges, L.论文数: 0 引用数: 0 h-index: 0机构: Inst Gustave Roussy, Dept Med Oncol, Villejuif, France Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceTannir, N.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceBurotto, M.论文数: 0 引用数: 0 h-index: 0机构: Bradford Hill Clin Res Ctr, Dept Med Oncol, Santiago, Chile Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceMcDermott, D. F.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Harvard Canc Ctr, Dept Med Oncol, Beth Israel Deaconess Med Ctr, Boston, MA USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FrancePlimack, E. R.论文数: 0 引用数: 0 h-index: 0机构: Fox Chase Canc Ctr, Dept Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceBarthelemy, P.论文数: 0 引用数: 0 h-index: 0机构: Hop Univ Strasbourg, Inst Cancerol Strasbourg ICANS Strasbourg, Med Oncol Unit, Strasbourg, France Inst Gustave Roussy, Dept Med Oncol, Villejuif, FrancePorta, C. G.论文数: 0 引用数: 0 h-index: 0机构: IRCCS San Matteo Univ Hosp Fdn, Dept Med Oncol, Pavia, Italy Inst Gustave Roussy, Dept Med Oncol, Villejuif, FrancePowles, T. B.论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Royal Free Natl Hlth Serv Trust, Canc Res UK Expt Canc Med Ctr, Dept Genitourinary Oncol,Barts Canc Inst, London, England Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceDonskov, F.论文数: 0 引用数: 0 h-index: 0机构: Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceGeorge, S.论文数: 0 引用数: 0 h-index: 0机构: Roswell Pk Canc Inst, Dept Med, Buffalo, NY USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceKollmannsberger, C.论文数: 0 引用数: 0 h-index: 0机构: British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada Inst Gustave Roussy, Dept Med Oncol, Villejuif, France论文数: 引用数: h-index:机构:Grimm, M-O.论文数: 0 引用数: 0 h-index: 0机构: Jena Univ Hosp, Dept Urol, Jena, Germany Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceTomita, Y.论文数: 0 引用数: 0 h-index: 0机构: Niigata Univ, Dept Mol Oncol, Grad Sch Med & Dent Sci, Dept Urol, Niigata, Japan Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceCastellano Gauna, D.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceRini, B. I.论文数: 0 引用数: 0 h-index: 0机构: Vanderbilt Univ, Div Hematol Oncol, Med Ctr, Nashville, TN USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceChoueiri, T. K.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceSaggi, S. S.论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Dept Clin Trials, Princeton, NJ USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceMcHenry, M. B.论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Dept Biostat, Princeton, NJ USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceMotzer, R. J.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
- [42] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Powles, Thomas论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandChoueiri, Toni K.论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandBurotto, Mauricio论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandEscudier, Bernard论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandBourlon, Maria Teresa论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandShah, Amishi Yogesh论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandSuarez, Cristina论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandHamzaj, Alketa论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandPorta, Camillo论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandHocking, Christopher论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandKessler, Elizabeth R.论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandGurney, Howard论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandTomita, Yoshihiko论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandBedke, Jens论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandZhang, Joshua论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandSimsek, Burcin论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandScheffold, Christian论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandApolo, Andrea B.论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, EnglandMotzer, Robert J.论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
- [43] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 TrialJAMA ONCOLOGY, 2019, 5 (02) : 187 - 194Ascierto, Paolo A.论文数: 0 引用数: 0 h-index: 0机构: Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyLong, Georgina V.论文数: 0 引用数: 0 h-index: 0机构: Melanoma Inst Australia, Sydney, NSW, Australia Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia Royal North Shore Hosp, Northern Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyRobert, Caroline论文数: 0 引用数: 0 h-index: 0机构: Inst Gustave Roussy, Dept Med, Villejuif, France Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyBrady, Benjamin论文数: 0 引用数: 0 h-index: 0机构: Cabrini Hlth, Med Oncol & Haematol, Melbourne, Vic, Australia Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyDutriaux, Caroline论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Bordeaux, Dermatol Serv, Bordeaux, France Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyDi Giacomo, Anna Maria论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Siena, UOC Oncol Immunotherapy, Ist Toscano Tumori, Siena, Italy Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyMortier, Laurent论文数: 0 引用数: 0 h-index: 0机构: Ctr Hosp Reg Univ Lille, INSERM, U1189, Clin Dermatol,Unite Oncodermatol, Lille, France Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyHassel, Jessica C.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany Natl Ctr Tumor Dis, Heidelberg, Germany Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyRutkowski, Piotr论文数: 0 引用数: 0 h-index: 0机构: Maria Sklodowska Curie Inst Oncol Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyMcNeil, Catriona论文数: 0 引用数: 0 h-index: 0机构: Melanoma Inst Australia, Chris OBrien Lifehouse, Camperdown, NSW, Australia Royal Prince Alfred Hosp, Camperdown, NSW, Australia Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyKalinka-Warzocha, Ewa论文数: 0 引用数: 0 h-index: 0机构: Polish Mothers Mem Hosp, Res Inst, Lodz, Poland Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalySavage, Kerry J.论文数: 0 引用数: 0 h-index: 0机构: BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyHernberg, Micaela M.论文数: 0 引用数: 0 h-index: 0机构: Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Mihalcioiu, Catalin论文数: 0 引用数: 0 h-index: 0机构: McGill Univ, Dept Oncol, Montreal, PQ, Canada Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyChiarion-Sileni, Vanna论文数: 0 引用数: 0 h-index: 0机构: IRCCS, Ist Oncol Veneto, Melanoma Canc Unit, Padua, Italy Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyMauch, Cornelia论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Cologne, Dept Dermatol, Cologne, Germany Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyCognetti, Francesco论文数: 0 引用数: 0 h-index: 0机构: Regina Elena Inst Canc Res, Div Oncol, Rome, Italy Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyNy, Lars论文数: 0 引用数: 0 h-index: 0机构: Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden Sahlgrens Univ Hosp, Gothenburg, Sweden Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyArance, Ana论文数: 0 引用数: 0 h-index: 0机构: Hosp Clin Barcelona, Barcelona, Spain Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalySvane, Inge Marie论文数: 0 引用数: 0 h-index: 0机构: Herlev Hosp, Ctr Canc Immune Therapy, Herlev, Denmark Copenhagen Univ Hosp, Dept Oncol, Herlev, Denmark Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalySchadendorf, Dirk论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Essen, Dept Dermatol, Essen, Germany German Canc Consortium, Heidelberg, Germany Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyGogas, Helen论文数: 0 引用数: 0 h-index: 0机构: Natl & Kapodistrian Univ Athens, Sch Med, Laiko Gen Hosp, Dept Med 1, Athens, Greece Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalySaci, Abdel论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Global Biometr Sci, Princeton, NJ USA Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyJiang, Joel论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Global Biometr Sci, Princeton, NJ USA Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyRizzo, Jasmine论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, ItalyAtkinson, Victoria论文数: 0 引用数: 0 h-index: 0机构: Univ Queensland, Princess Alexandra Hosp, Woolloongabba, Qld, Australia Greenslopes Private Hosp, Gallipoli Med Res Fdn, Greenslopes, Qld, Australia Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy
- [44] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319Motzer, R. J.论文数: 0 引用数: 0 h-index: 0Powles, T.论文数: 0 引用数: 0 h-index: 0Burotto, M.论文数: 0 引用数: 0 h-index: 0
- [45] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404Vergote, I论文数: 0 引用数: 0 h-index: 0Gonzalez-Martin, A.论文数: 0 引用数: 0 h-index: 0Lorusso, D.论文数: 0 引用数: 0 h-index: 0
- [46] Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2020, 21 (12): : 1563 - 1573Powles, Thomas论文数: 0 引用数: 0 h-index: 0机构: Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, England Queen Mary Univ London, London, England Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandPlimack, Elizabeth R.论文数: 0 引用数: 0 h-index: 0机构: Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandSoulieres, Denis论文数: 0 引用数: 0 h-index: 0机构: Ctr Hosp Univ Montreal, Montreal, PQ, Canada Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandWaddell, Tom论文数: 0 引用数: 0 h-index: 0机构: Christie NHS Fdn Trust, Manchester, Lancs, England Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandStus, Viktor论文数: 0 引用数: 0 h-index: 0机构: Minist Hlth Ukraine, Dnipropetrovsk Med Acad, Dnipro, Ukraine Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandGafanov, Rustem论文数: 0 引用数: 0 h-index: 0机构: Russian Sci Ctr Roentgenoradiol, Moscow, Russia Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandNosov, Dmitry论文数: 0 引用数: 0 h-index: 0机构: Cent Clin Hosp Outpatient Clin, Moscow, Russia Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, England论文数: 引用数: h-index:机构:Melichar, Bohuslav论文数: 0 引用数: 0 h-index: 0机构: Palacky Univ, Med Sch & Teaching Hosp, Olomouc, Czech Republic Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandVynnychenko, Ihor论文数: 0 引用数: 0 h-index: 0机构: Sumy State Univ, Sumy Reg Oncol Ctr, Sumy Oblast, Ukraine Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandAzevedo, Sergio J.论文数: 0 引用数: 0 h-index: 0机构: Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandBorchiellini, Delphine论文数: 0 引用数: 0 h-index: 0机构: Univ Cote dAzur, Ctr Antoine Lacassagne, Nice, France Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandMcDermott, Raymond S.论文数: 0 引用数: 0 h-index: 0机构: Ireland Univ Coll Dublin, Adelaide & Meath Hosp, Dublin, Ireland Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandBedke, Jens论文数: 0 引用数: 0 h-index: 0机构: Eberhard Karls Univ Tubingen, Univ Hosp, Tubingen, Germany Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandTamada, Satoshi论文数: 0 引用数: 0 h-index: 0机构: Osaka City Univ Hosp, Osaka, Japan Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandYin, Lina论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandChen, Mei论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandMolife, L. Rhoda论文数: 0 引用数: 0 h-index: 0机构: Merck Sharp & Dohme UK, London, England Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandAtkins, Michael B.论文数: 0 引用数: 0 h-index: 0机构: Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, EnglandRini, Brian, I论文数: 0 引用数: 0 h-index: 0机构: Cleveland Clin Taussig Canc Inst, Cleveland, OH USA Vanderbilt Ingram Canc Ctr, Nashville, TN USA Barts Canc Inst, Barts Hlth NHS Trust & Royal Free NHS Fdn Trust, London, England
- [47] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2022, 23 (02): : 292 - 303Cella, David论文数: 0 引用数: 0 h-index: 0机构: Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAMotzer, Robert J.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USASuarez, Cristina论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USABlum, Steven, I论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Princeton, NJ USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAEjzykowicz, Flavia论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Princeton, NJ USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAHamilton, Melissa论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Princeton, NJ USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAWallace, Joel F.论文数: 0 引用数: 0 h-index: 0机构: Exelixis, Alameda, CA USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USASimsek, Burcin论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Princeton, NJ USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAZhang, Joshua论文数: 0 引用数: 0 h-index: 0机构: Bristol Myers Squibb, Princeton, NJ USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAIvanescu, Cristina论文数: 0 引用数: 0 h-index: 0机构: IQVIA, Amsterdam, Netherlands Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAApolo, Andrea B.论文数: 0 引用数: 0 h-index: 0机构: NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USAChoueiri, Toni K.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
- [48] Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial (vol 6, pg 1247, 2020)JAMA ONCOLOGY, 2020, 6 (09) : 1473 - 1473Choueiri, T. K.论文数: 0 引用数: 0 h-index: 0Heng, D. Y. C.论文数: 0 引用数: 0 h-index: 0Lee, J. L.论文数: 0 引用数: 0 h-index: 0
- [49] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 studyONKOUROLOGIYA, 2022, 18 (02): : 39 - 57Motzer, R.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA论文数: 引用数: h-index:机构:Alekseev, B.论文数: 0 引用数: 0 h-index: 0机构: PA Herzen Moscow Oncol Res Inst, Dept Oncourol, Moscow, Russia Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USARha, S. Y.论文数: 0 引用数: 0 h-index: 0机构: Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAChoueiri, T. K.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAMendez-Vidal, M. J.论文数: 0 引用数: 0 h-index: 0机构: Univ Reina Sofia, Maimonides Inst Biomed Res, Cordoba Hosp, Cordoba, Spain Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA论文数: 引用数: h-index:机构:Kapoor, A.论文数: 0 引用数: 0 h-index: 0机构: McMaster Univ, Hamilton, ON, Canada Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAGoh, J. C.论文数: 0 引用数: 0 h-index: 0机构: ICON Res, South Brisbane, Australia Queensland Univ Technol, Brisbane, Qld, Australia Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAEto, M.论文数: 0 引用数: 0 h-index: 0机构: Kyushu Univ, Fukuoka, Japan Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USABennett, L.论文数: 0 引用数: 0 h-index: 0机构: RTI Hlth Solut, Res Triangle Pk, NC USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAWang, J.论文数: 0 引用数: 0 h-index: 0机构: RTI Hlth Solut, Res Triangle Pk, NC USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAPan, J. J.论文数: 0 引用数: 0 h-index: 0机构: Eisai, Nutley, NJ USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USASaretsky, T. L.论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAPerini, R. F.论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAHe, C. S.论文数: 0 引用数: 0 h-index: 0机构: Eisai, Nutley, NJ USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USAMody, K.论文数: 0 引用数: 0 h-index: 0机构: Eisai, Nutley, NJ USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USACella, D.论文数: 0 引用数: 0 h-index: 0机构: Northwestern Univ, Dept Med Social Sci, Chicago, IL USA Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
- [50] Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial (vol 5, pg 187, 2018)JAMA ONCOLOGY, 2019, 5 (02) : 271 - 271Ascierto, P. A.论文数: 0 引用数: 0 h-index: 0Long, G., V论文数: 0 引用数: 0 h-index: 0Robert, C.论文数: 0 引用数: 0 h-index: 0